Quick Dispatch:
Your summit study tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your summit study tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ships.
Need Help?
Questions about summit study tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for summit study tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial in your area.
Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity
22.94
SURMOUNT-3 study design This is a phase 3, multicenter, randomized,
27.00
Has Tirzepatide Scaled the HFpEF/Obesity SUMMIT?
21.90
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists
20.29
💊 New research in obesity & heart failure The SUMMIT study looked at tirzepatide, a once-weekly injection, in people with both obesity and heart failure with preserved ejection fraction (HFpEF). Over 52
28.51
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM 🥸The SUMMIT trial
27.91
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology
29.04
